FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Jun. 30, 2025

Schedule of Fair Value on a Recurring Basis

The following table presents the Company’s assets, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of June 30, 2025 (in thousands):


	As of June 30, 2025
	Total carrying and estimated fair value		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets:
Cash and cash equivalents	$	75,154	$	75,154	$	—	$	—
Marketable debt securities, available-for-sale	244,383		—		244,383		—
Total	$	319,537	$	75,154	$	244,383	$	—


	As of December 31, 2024
	Total carrying and estimated fair value		Quoted prices in active markets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets:
Cash and cash equivalents	$	58,535	$	51,060	$	7,475	$	—
Marketable debt securities, available-for-sale	312,166		—		312,166		—
Total	$	370,701	$	51,060	$	319,641	$	—

Travere Therapeutics, Inc. 10-Q